| Literature DB >> 32355183 |
Chia-Lun Li1,2, Yu-Ching Chen1, Kuo-Chung Yang1,2, Lee-Wei Chen3,4,5.
Abstract
Asian population is a low-risk group for basal cell carcinoma (BCC) and there is little data available in this setting. Sun-exposed BCC (SEBCC) may possess a different pathogenic mechanism from non-sun-exposed BCC (NSEBCC). To compare the histopathological profiles and outcomes between SEBCC and NSEBCC, and to assess the risk factors for tumor recurrences. Retrospective cohort study on 372 patients with pathologically diagnosed BCC from January 1, 1990 to August 31, 2017. Data were derived from a single medical center in Taiwan. SEBCC presented with higher Clark level and more high-risk factors for recurrence than NSEBCC. Nodular, micronodular, infiltrating/mixed infiltrating, basosquamous, and adenoid types were predominant in SEBCC, as superficial type in NSEBCC. Risk factors for recurrence included infiltrating/mixed-infiltrating subtypes and synchronous basosquamous cell carcinoma. No recurrence events were observed in NSEBCC. Our study showed an acceptable recurrence rate (4.2%) of the whole population after excision even under a smaller surgical margin width than suggested by current guidelines. SEBCC had a higher recurrence rate with a significantly different tumor characteristic from NSEBCC and a greater tumor depth than NSEBCC. A wider surgical margin in SEBCC than NSEBCC is suggested.Entities:
Mesh:
Year: 2020 PMID: 32355183 PMCID: PMC7193595 DOI: 10.1038/s41598-020-64391-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Study population characteristics (n = 372).
| Patient with SEBCC | Patient with NSEBCC | p-value | |
|---|---|---|---|
| Patient number (%) | 338 (90.9%) | 34 (9.1%) | — |
| Men/ Women (n) | 213/125 | 23/11 | p = 0.593 |
| Age at onset, mean ± SD (range) | 71.8 ± 13.7 (11-99) | 70.5 ± 12.1 (43-86) | p = 0.576* |
| Duration of follow up (year), mean ± SD (range) | 4.51 ± 4.2 (0-26) | 4.94 ± 4.3 (0-19) | p = 0.564* |
| Co-morbidities (%) | |||
| DM | 89 (26.3) | 7 (20.6) | p = 0.466 |
| HT | 156 (46.2) | 17 (50.0) | p = 0.668 |
| CKD | 24 (7.1) | 6 (17.6) | p = 0.031 |
| ESRD | 11 (3.3) | 0 (0) | p = 0.609 |
| CVA | 37 (10.9) | 1 (2.9) | p = 0.231 |
| CAD | 29 (8.6) | 2 (5.9) | p = 0.999 |
| Arrhythmia | 22 (6.5) | 3 (8.8) | p = 0.489 |
| VHD | 5 (1.5) | 0 (0) | p = 0.999 |
| ILD | 3 (0.9) | 0 (0) | p = 0.999 |
| Asthma | 2 (0.6) | 0 (0) | p = 0.999 |
| COPD | 4 (1.2) | 0 (0) | p = 0.999 |
| Dementia | 11 (3.3) | 2 (5.9) | p = 0.337 |
| Heart failure | 7 (2.1) | 1 (2.9) | p = 0.539 |
| RA | 0 (0) | 2 (5.9) | p = 0.008 |
| Gout | 8 (2.4) | 3 (8.8) | p = 0.069 |
| Hyperthyroidism | 1 (0.3) | 1 (2.9) | p = 0.175 |
| HBV infection | 7 (2.1) | 1 (2.9) | p = 0.539 |
| HCV infection | 9 (2.7) | 1 (2.9) | p = 0.999 |
| Hepatitis | 3 (0.9) | 1 (2.9) | p = 0.320 |
| Liver cirrhosis | 5 (1.5) | 0 (0) | p = 0.999 |
| Anemia | 6 (1.8) | 2 (5.9) | p = 0.160 |
| Tuberculosis | 1 (0.3) | 1 (2.9) | p = 0.175 |
| GI disease | 36 (10.7) | 0 (0) | p = 0.060 |
| Arsenism | 6 (1.8) | 2 (5.9) | p = 0.160 |
| Immunocompromised | 121 (35.8) | 17 (50) | p = 0.135 |
DM: diabetes mellitus; HT: hypertension; CKD: chronic kidney disease; ESRD: end-stage renal disease; CVA: cerebral vascular accident; CAD: coronary artery disease; VHD: valvular heart disease; ILD: interstitial lung disease; COPD: chronic obstructive pulmonary disease; RA: rheumatoid arthritis; HBV: hepatitis B virus; HCV: hepatitis C virus; GI: gastrointestinal; N: number; SD: standard deviation. Using two sample t-test (*), otherwise chi-square test or Fisher’s exact test. p-value <0.05: two-tailed statistical significance.
Tumor site of all BCC lesions.
| Tumor site (N = 403 BCCs) | No. of BCCs (%) |
|---|---|
| Head and neck | 355 (88.1) |
| Nose or surroundings of nose | 119 (29.5) |
| Nasolabial fold | 19 (4.7) |
| Cheeks and zygomatic area | 56 (13.9) |
| Lips and supralabial area | 13 (3.2) |
| Eyebrows or area surrounding the eye | 50 (12.4) |
| Forehead and glabella | 12 (3.0) |
| Temporal areas | 7 (1.7) |
| Ears and periauricular areas | 35 (8.7) |
| Chin | 6 (1.5) |
| Scalp | 32 (7.9) |
| Neck | 6 (1.5) |
| Trunk | 24 (6.0) |
| Back and shoulder | 10 (2.5) |
| Axillary | 2 (0.5) |
| Thorax | 6 (1.5) |
| Abdomen | 6 (1.5) |
| Extremities | 18 (4.5) |
| Upper arm | 2 (0.5) |
| Forearm | 3 (0.7) |
| Wrist | 2 (0.5) |
| Thigh | 7 (1.7) |
| Lower leg | 3 (1.7) |
| Popliteal | 1 (0.2) |
| Other, pelvic, anogenital area, or buttocks | 6 (1.5) |
The crude and adjusted odds ratio of area of BCC, patient demographics, or comorbidities associated with the development of multiple BCCs by logistic regression analyses.
| Multiple, n (%) | Singular, n (%) | COR (95% CI) | p-value | AOR (95% CI) | p-value | ||
|---|---|---|---|---|---|---|---|
| Lesion of sun-exposed area | 18 (81.8) | 320 (91.4) | 0.42 (0.13-1.33) | 0.140 | 0.55 (0.16-1.90) | 0.342 | |
| Age | <65.0 | 3 (13.6) | 91 (26.0) | 1 [Reference] | |||
| 65.0–74.99 | 7 (31.8) | 85 (24.3) | 2.45 (0.63–9.97) | 0.195 | 2.43 (0.58–10.25) | 0.228 | |
| >=75.0 | 12 (54.5) | 174 (49.7) | 2.09 (0.58–7.60) | 0.262 | 2.03 (0.51–8.13) | 0.316 | |
| Sex (men) | 13 (59.1) | 223 (63.7) | 0.82 (0.34–1.98) | 0.663 | 0.68 (0.27–1.70) | 0.406 | |
| DM | 5 (22.7) | 91 (26.0) | 0.84 (0.30–2.33) | 0.734 | 0.71 (0.22–2.28) | 0.560 | |
| HT | 11 (50.0) | 162 (46.3) | 1.16 (0.49–2.47) | 0.735 | 0.92 (0.34–2.49) | 0.875 | |
| CKD | 2 (9.1) | 28 (8.0) | 1.15 (0.26–5.17) | 0.855 | 0.54 (0.07–4.07) | 0.551 | |
| Gout | 2 (9.1) | 9 (2.6) | 3.79 (0.77–18.71) | 0.102 | 7.32 (0.85–62.98) | 0.070 | |
| Dementia | 3 (13.6) | 10 (2.9) | 5.37 (1.36–21.14) | 0.016 | 5.84 (1.34–25.58) | 0.019 | |
| Arsenism | 1 (4.5) | 4 (1.1) | 4.12 (0.44–38.50) | 0.214 | 3.40 (0.31–36.66) | 0.314 | |
DM: diabetes mellitus; HT: hypertension; CKD: chronic kidney disease; COR: crude odds ratio, AOR: adjusted odds ratio; CI: confidence interval. p-value <0.05: two-tailed statistical significance.
Histopathologic characteristics of BCC lesions.
| SEBCC | NSEBCC | p-value | |
|---|---|---|---|
| Lesion number (%) | 363 (90.1%) | 40 (9.9%) | |
| Dimension (cm), mean ± SD | 1.10 ± 1.07 | 1.96 ± 1.52 | p = 0.002* |
| Depth (mm), mean ± SD | 3.34 ± 2.42 | 3.19 ± 6.54 | p = 0.904* |
| Clark level (%) | p < 0.001 | ||
| I | 0 (0.0) | 0 (0.0) | |
| II | 5 (0.4) | 3 (11.5) | |
| III | 1 (0.4) | 4 (15.4) | |
| IV | 212 (84.1) | 17 (65.4) | |
| V | 34 (13.5) | 2 (7.7) | |
| Margin free (%) | 258 (91.5) | 28 (90.3) | p = 0.826 |
| Closest margin distance (mm), mean ± SD (range) | 2.01 ± 1.46 (0.1–9.0) | 3.77 ± 2.08 (0.5–8.0) | p < 0.001* |
| High risk features n. (mean ± SD) | 1.63 ± 0.59 | 1.04 ± 0.77 | p < 0.001* |
| Depth> 2 mm | 200 (62.7) | 8 (29.6) | p = 0.001 |
| Clark level ≥ 4 | 247 (97.6) | 19 (73.1) | p < 0.001 |
| Lesions on ear or lip (%) | 22 (6.1) | 0 (0.0) | p = 0.149 |
| Perineural invasion (%) | 2 (0.8) | 0 (0.0) | p > 0.999 |
| Histopathology (%) | p < 0.001 | ||
| Nodular | 203 (82.2) | 16 (55.2) | |
| Micronodular | 6 (2.4) | 0 (0.0) | |
| Superficial | 8 (3.2) | 7 (24.1) | |
| Infiltrating or mixed-infiltrating | 13 (5.3) | 0 (0.0) | |
| Morpheaform | 3 (1.2) | 1 (3.4) | |
| Basosquamous | 3 (1.2) | 0 (0.0) | |
| Adenoid | 1 (0.4) | 0 (0.0) | |
| Other | 10 (4.0) | 5 (17.2) | |
| AJCC Staging (%) | p = 0.314 | ||
| Stage 1 | 95 (39.1) | 14 (53.8) | |
| Stage 2 | 145 (59.7) | 12 (46.2) | |
| Stage 3 | 3 (1.2) | 0 (0.0) | |
N: number; SD: standard deviation; AJCC: American Joint Committee on Cancer (AJCC) 7th edition of cutaneous squamous cell carcinoma (cSCC) extrapolated in BCCs. Using two sample t-test (*), otherwise chi-square test or Fisher’s exact test. p-value <0.05: two-tailed statistical significance.
The adjusted hazard ratio (aHR) of patient demographics and comorbidities associated with recurrence of BCC.
| Recurrence (%) | Non-recurrence (%) | HR (95% CI) | p-value | aHR (95% CI) | p-value | ||
|---|---|---|---|---|---|---|---|
| Age of index lesion | <65.0 | 5 (29.4) | 93 (24.1) | 1 [Reference] | |||
| 65.0–74.99 | 4 (23.5) | 96 (24.9) | 0.77 (0.21–2.89) | 0.703 | 0.43 (0.05–3.37) | 0.419 | |
| >= 75.0 | 8 (47.1) | 197 (51.0) | 1.30 (0.40–4.22) | 0.659 | 0.39 (0.08–2.06) | 0.269 | |
| Sex (men) | 11 (64.7) | 242 (62.7) | 0.91 (0.33–2.46) | 0.845 | 0.99 (0.26–3.80) | 0.991 | |
| DM | 5 (29.4) | 99 (25.6) | 1.38 (0.48–3.93) | 0.548 | 0.45 (0.07–2.77) | 0.391 | |
| HT | 10 (58.8) | 178 (46.1) | 1.91 (0.72–5.08) | 0.194 | 3.07 (0.70–13.46) | 0.137 | |
| ESRD | 2 (11.8) | 12 (3.1) | 4.63 (1.04–20.66) | 0.045 | 1.55 (0.10–23.36) | 0.751 | |
| Infiltrating or mixed-infiltrating subtype | 2 (16.7) | 11 (4.2) | 3.20 (0.62–16.47) | 0.165 | 6.17 (1.07–35.64) | 0.042 | |
| Synchronous basosquamous cell carcinoma | 2 (11.8) | 4 (1.0) | 12.01 (2.66–54.50) | 0.001 | 16.84 (1.31–216.92) | 0.030 | |
DM: diabetes mellitus; HT: hypertension; ESRD: end-stage renal disease; HR: hazard ratio, aHR: adjusted hazard ratio; CI: confidence interval. p-value < 0.05: two-tailed statistical significance. Adjusted HRs based on Cox proportional hazards were calculated after adjustment for age, sex, diabetes, hypertension, end stage renal disease, and synchronous basosquamous cell carcinoma.
Figure 1Cox regression survival curve of recurrence rate of BCC associated with synchronous basosquamous cell carcinoma and infiltrating or mixed-infiltrating type BCC.
Figure 2Study design and flowchart of patient selection.